CRISPR Therapeutics (NASDAQ:CRSP) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report issued on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $65.00 price objective on the stock. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, FY2024 earnings at ($4.83) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

A number of other analysts have also recently commented on the company. Bank of America reduced their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays lowered their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Finally, JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Trading Up 4.3 %

CRSP opened at $42.22 on Monday. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. The company has a market cap of $3.60 billion, a price-to-earnings ratio of -14.92 and a beta of 1.67. The company’s 50 day moving average is $43.20 and its 200 day moving average is $46.82.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm posted ($1.41) EPS. As a group, analysts predict that CRISPR Therapeutics will post -5.1 EPS for the current fiscal year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in shares of CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares during the last quarter. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. Van ECK Associates Corp increased its position in shares of CRISPR Therapeutics by 5,269.3% during the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after purchasing an additional 81,464 shares during the last quarter. Finally, KBC Group NV raised its holdings in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after buying an additional 57,696 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.